Inflammatory bowel disease (IBD) is multifactorial, resulting from a complex interplay of genetic predisposition, environmental factors, immune dysregulation, and microorganisms within the intestine.1 Available therapies have focused almost exclusively on suppressing the aberrant host immune response. Although biologic agents have improved the clinical outcomes for patients with Crohn disease and ulcerative colitis (UC), concerns related to risk of infection and malignancy cause anxiety for clinicians and patients, who must be treated with these medications long-term. Patients with IBD have been shown to have alterations in gut microbiota such as lower diversity of microorganisms and increased numbers of proinflammatory and enteroadherent bacterial species,2 but whether these alterations are a cause or consequence of the disease state is unclear. Nevertheless, as the efficacy and safety of fecal microbiota transplantation (FMT) for treatment of Clostridium difficile infection (CDI) has become increasingly recognized,3 interest in FMT as a primary treatment for other conditions associated with imbalance in the intestinal microbiome, such as IBD, has also increased.
Kelly CR, Ananthakrishnan AN. Manipulating the Microbiome With Fecal Transplantation to Treat Ulcerative Colitis. JAMA. 2019;321(2):151–152. doi:10.1001/jama.2018.20397
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.